Furthermore, the study broadens our understanding of PCK1 in HCC progression and metastasis, and indicate that targeting O-GlcNAcylation has the potential to become a novel strategy for HCC therapy. This evidence concerns the gene PCK1 and hepatocellular carcinoma.